Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Avanzi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Revue Medicale Suisse|January 22, 2015
[Lungs et diving]F Héritier, P Avanzi, L Nicod
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Emerging Role of CAR T Cells in Non-Hodgkin's LymphomaMauro P Avanzi, Renier J Brentjens
British Journal of Haematology|February 14, 2014
Ex vivo production of platelets from stem cellsMauro P Avanzi, William Beau Mitchell
Transfusion|May 23, 2012
Optimizing megakaryocyte polyploidization by targeting multiple pathways of cytokinesisMauro P Avanzi, Amanda Chen, Wu He, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumorsMirella Nardo, Tatiane C Motta, Leandro M Colli, et al.
Plos One|April 16, 2015
Actin inhibition increases megakaryocyte proplatelet formation through an apoptosis-dependent mechanismMauro P Avanzi, Marina Izak, Oluwasijibomi E Oluwadara, et al.
British Journal of Haematology|January 4, 2014
Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulationMauro P Avanzi, Francine Goldberg, Jennifer Davila, et al.
Transfusion|October 16, 2015
A novel bioreactor and culture method drives high yields of platelets from stem cellsMauro P Avanzi, Oluwasijibomi E Oluwadara, Melissa M Cushing, et al.
Cell Reports|May 17, 2018
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune SystemMauro P Avanzi, Oladapo Yeku, Xinghuo Li, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Revue Medicale Suisse|January 22, 2015
[Lungs et diving]F Héritier, P Avanzi, L Nicod
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Emerging Role of CAR T Cells in Non-Hodgkin's LymphomaMauro P Avanzi, Renier J Brentjens
British Journal of Haematology|February 14, 2014
Ex vivo production of platelets from stem cellsMauro P Avanzi, William Beau Mitchell
Transfusion|May 23, 2012
Optimizing megakaryocyte polyploidization by targeting multiple pathways of cytokinesisMauro P Avanzi, Amanda Chen, Wu He, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumorsMirella Nardo, Tatiane C Motta, Leandro M Colli, et al.
Plos One|April 16, 2015
Actin inhibition increases megakaryocyte proplatelet formation through an apoptosis-dependent mechanismMauro P Avanzi, Marina Izak, Oluwasijibomi E Oluwadara, et al.
British Journal of Haematology|January 4, 2014
Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulationMauro P Avanzi, Francine Goldberg, Jennifer Davila, et al.
Transfusion|October 16, 2015
A novel bioreactor and culture method drives high yields of platelets from stem cellsMauro P Avanzi, Oluwasijibomi E Oluwadara, Melissa M Cushing, et al.
Cell Reports|May 17, 2018
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune SystemMauro P Avanzi, Oladapo Yeku, Xinghuo Li, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Pageof 1